1 Ocak 2010 Dergi makalesi Açık Erişim

Barbai, V. H.; Ujhelyi, E.; Szlavik, J.; Vietorisz, I.; Varga, L.; Fey, E.; Fust, G.; Banhegyi, D.

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 27023, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@type": "Person", 
      "affiliation": "Fovarosi Onkormanyzat Egyesitett Szent Istvan & S, Dept Immunol, H-1097 Budapest, Hungary", 
      "name": "Barbai, V. H."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Fovarosi Onkormanyzat Egyesitett Szent Istvan & S, Dept Immunol, H-1097 Budapest, Hungary", 
      "name": "Ujhelyi, E."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Fovarosi Onkormanyzat Egyesitett Szent Istvan & S, Dept Trop Dis, H-1097 Budapest, Hungary", 
      "name": "Szlavik, J."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Fovarosi Onkormanyzat Egyesitett Szent Istvan & S, Dept Clin Chem, H-1097 Budapest, Hungary", 
      "name": "Vietorisz, I."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Semmelweis Univ, Dept Internal Med 3, Budapest, Hungary", 
      "name": "Varga, L."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Fovarosi Onkormanyzat Egyesitett Szent Istvan & S, Dept Clin Chem, H-1097 Budapest, Hungary", 
      "name": "Fey, E."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Semmelweis Univ, Dept Internal Med 3, Budapest, Hungary", 
      "name": "Fust, G."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Fovarosi Onkormanyzat Egyesitett Szent Istvan & S, Dept Trop Dis, H-1097 Budapest, Hungary", 
      "name": "Banhegyi, D."
    }
  ], 
  "datePublished": "2010-01-01", 
  "description": "P>Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-1 infected patients is well documented and generally used, but there is limited information about the changes of acute-phase protein (APP) levels in response to this treatment. Fifteen patients undergoing highly active anti-retroviral therapy (HAART) treatment, with undetectable viral load, but low CD4+ cell count (< 300/mu l), have been treated with 3 center dot 6 M IU Proleukine (R) administered twice daily by subcutaneous injection over 5 days. C-reactive protein (CRP), d-dimer, C3, C9, C1-inh and alpha-2HS glycoprotein levels were measured immediately before IL-2 administration, as well as on day 5 and 2-3 weeks thereafter. After IL-2 administration, both mean d-dimer and CRP levels increased significantly (P < 0 center dot 001), but returned (P < 0 center dot 001) to baseline within the subsequent 2-3 weeks. Alpha-2HS glycoprotein decreased immediately after IL-2 administration. No significant differences were detected in the levels of C3, C9 and C1-inh. A significant, positive correlation (r = 0 center dot 5178, P = 0 center dot 0008) was ascertained between the changes of CRP level, measured immediately before as well as 5 days after IL-2 administration, and changes in CD4 T cell counts measured 2-3 weeks before and after treatment, respectively. IL-2 administration induces rapid elevation of two major APPs (CRP, d-dimer). The positive correlation observed between the changes of CRP levels and CD4+ cell counts after IL-2 administration may indicate that the abrupt, but transitory overproduction of CRP might contribute to the CD4+ cell count-increasing effect of the drug and/ or may be associated with serious side effects.", 
  "headline": "Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment", 
  "identifier": 27023, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "license": "http://www.opendefinition.org/licenses/cc-by", 
  "name": "Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment", 
  "url": "https://aperta.ulakbim.gov.tr/record/27023"
}